Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q63ZY3

UPID:
KANK2_HUMAN

ALTERNATIVE NAMES:
Ankyrin repeat domain-containing protein 25; Matrix-remodeling-associated protein 3; SRC-1-interacting protein

ALTERNATIVE UPACC:
Q63ZY3; B0I1P4; Q3KQZ3; Q6GUF5; Q9H8S4; Q9NUP0; Q9P210

BACKGROUND:
The protein KN motif and ankyrin repeat domain-containing protein 2, with alternative names such as Ankyrin repeat domain-containing protein 25, Matrix-remodeling-associated protein 3, and SRC-1-interacting protein, is integral to cell function. It regulates transcription, apoptosis, vitamin D receptor signaling, and cell migration through its effects on the Rho signaling pathway and interaction with ARHGDIA. Its role in actin stress fibers formation is vital for cell adhesion and migration, particularly in kidney development.

THERAPEUTIC SIGNIFICANCE:
Linked to diseases like Palmoplantar keratoderma and woolly hair, and Nephrotic syndrome 16, KN motif and ankyrin repeat domain-containing protein 2 represents a promising target for drug discovery. Understanding its role could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.